An increase of approximately 94% from last year. Completed approximately 199,300 clinical therapy selection cases, an increase of 22% and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences partners with Everlywell to launch Caris Detect
- Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI
- Caris Life Sciences price target raised to $30 from $28 at Canaccord
- BLSH, SLMT, CAI: Cathie Wood Loads Up on Crypto and Healthcare Stocks, Trims a Consumer Tech Name
- Caris Life Sciences partners with Roche’s Genentechh for cancer targets
